Health Technology · Pharmaceuticals: Other · NSE: LUPIN · data 2026-10-09
Lupin Limited
Health check: Strong (8.3/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹1,956.5
Market cap
₹88,806 cr
P/E
16.2
P/B
—
ROE
26.9%
ROCE
30.7%
Debt / equity
0.3
Dividend yield
0.93%
1-year return
1.2%
52-week high
₹2,529.5
52-week low
₹1,900
Operating margin
25.2%
Growth
| Revenue (last 12 months) | ₹29,967 cr |
| Net profit (last 12 months) | ₹5,529 cr |
| Sales growth, 3 years (yearly) | 18.8% |
| Profit growth, 3 years (yearly) | 131.5% |
Similar companies
Cipla Ltd (CIPLA) · Aurobindo Pharma Ltd (AUROPHARMA) · Granules India Limited (GRANULES) · Sudeep Pharma Limited (SUDEEPPHRM) · Amrutanjan Health Care Limited (AMRUTANJAN)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open LUPIN in NSE Scanner →